PASADENA, Calif. --(BUSINESS WIRE)--Jul. Using the broadest portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Find the latest Arrowhead Pharmaceuticals, Inc. (ARWR) stock quote, history, news and other vital information to help you with your stock trading and investing. It theoretically can silence any disease-related genes in a sequence-specific manner, making small interfering RNA (siRNA) a promising therapeutic moRNA interference (RNAi) is an ancient biological mechanism used to defend against external invasion. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. Currency in USDCoronavirus: UK builders axe jobs despite rebound as 'chilly autumn' loomsLow-cost ways to build a retirement plan amid market uncertainty It theoretically can silence any disease-related genes in a sequence-specific manner, making small interfering RNA (siRNA) a promising therapeutic moArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2020 Earnings Conference Call August 05, 2020 4:30 PM ET Company Participants Vincent Anzalone - Vice President of Investor Relations Christopher Anzalone - President & Chief Executive Officer JaviArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2020 Earnings Conference Call August 05, 2020 4:30 PM ET Company Participants Vincent Anzalone - Vice President of Investor Relations Christopher Anzalone - President & Chief Executive Officer JaviDiscover new investment ideas by accessing unbiased, in-depth investment researchNasdaqGS - NasdaqGS Real Time Price. It theoretically can silence any disease-related genes in a sequence-specific manner, making small interfering RNA (siRNA) a promising therapeutic moArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2020 Earnings Conference Call August 05, 2020 4:30 PM ET Company Participants Vincent Anzalone - Vice President of Investor Relations Christopher Anzalone - President & Chief Executive Officer JaviArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2020 Earnings Conference Call August 05, 2020 4:30 PM ET Company Participants Vincent Anzalone - Vice President of Investor Relations Christopher Anzalone - President & Chief Executive Officer JaviDiscover new investment ideas by accessing unbiased, in-depth investment researchNasdaqGS - NasdaqGS Real Time Price. Find the latest Arrowhead Pharmaceuticals, Inc. (ARWR) stock discussions in Yahoo Finance's forum. PASADENA, Calif. --(BUSINESS WIRE)--May 1, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the retirement of Bruce Given , M.D., Arrowhead’s chief operating officer and head of R&D, which was previously planned and disclosed, after a more than 30-year career in biotechnology Find the latest Arrowhead Pharmaceuticals, Inc. (ARWR) stock quote, history, news and other vital information to help you with your stock trading and investing. Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q2 2020 Results - … 8, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2020 , at 4:30 p.m. EDT to discuss its financial results for the fiscal third quarter ended June 30, 2020 .